{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FDC&page=6", "query": { "condition": "FDC", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 144, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FDC&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FDC&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T06:08:37.809Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00549510", "title": "Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "COREG CR and lisinopril (FDC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 29, "start_date": "2007-10", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2010-10-15", "last_synced_at": "2026-10-20T06:08:37.809Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00549510" }, { "nct_id": "NCT02639338", "title": "Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "SOF/VEL/VOX", "type": "DRUG" }, { "name": "SOF/VEL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2015-12-23", "completion_date": "2017-01-02", "has_results": true, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-10-20T06:08:37.809Z", "location_count": 30, "location_summary": "Long Beach, California • Los Angeles, California • Palo Alto, California + 27 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Rialto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02639338" }, { "nct_id": "NCT07771465", "title": "A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Symptomatic Genetic Dilated Cardiomyopathy (DCM)" ], "interventions": [ { "name": "Danicamtiv", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kardigan, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 332, "start_date": "2026-08-26", "completion_date": "2033-01", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-20T06:08:37.809Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07771465" }, { "nct_id": "NCT06733675", "title": "Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer", "Pharmacokinetics", "Safety", "Drug-Drug Interaction (DDI)", "FDC" ], "interventions": [ { "name": "Ledaborbactam etzadroxil", "type": "DRUG" }, { "name": "Ceftibuten", "type": "DRUG" }, { "name": "Ceftibuten-ledaborbactam etzadroxil", "type": "DRUG" }, { "name": "Esomeprazole", "type": "DRUG" }, { "name": "amoxicillin-clavulanate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Basilea Pharmaceutica", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 96, "start_date": "2025-01-07", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-10-20T06:08:37.809Z", "location_count": 1, "location_summary": "Lenexa, Kansas", "locations": [ { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06733675" }, { "nct_id": "NCT02384395", "title": "Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV", "Acute HIV Infection" ], "interventions": [ { "name": "Dolutegravir 50 mg", "type": "DRUG" }, { "name": "Lamivudine 300 mg", "type": "DRUG" }, { "name": "Abacavir 600 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2015-09", "completion_date": "2021-09-17", "has_results": true, "last_update_posted_date": "2021-11-22", "last_synced_at": "2026-10-20T06:08:37.809Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Durham, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02384395" }, { "nct_id": "NCT05577182", "title": "Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancies" ], "interventions": [ { "name": "INCA32459-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2023-01-05", "completion_date": "2025-10-13", "has_results": false, "last_update_posted_date": "2025-11-03", "last_synced_at": "2026-10-20T06:08:37.809Z", "location_count": 2, "location_summary": "Los Angeles, California • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05577182" }, { "nct_id": "NCT07619118", "title": "A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolaemia" ], "interventions": [ { "name": "laroprovstat/rosuvastatin 1", "type": "COMBINATION_PRODUCT" }, { "name": "laroprovstat/rosuvastatin 2", "type": "COMBINATION_PRODUCT" }, { "name": "laroprovstat/rosuvastatin 3", "type": "COMBINATION_PRODUCT" }, { "name": "laroprovstat/rosuvastatin 4", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo to match laroprovstat/rosuvastatin 1,2,3", "type": "DRUG" }, { "name": "Placebo to match laroprovstat/rosuvastatin 4", "type": "DRUG" }, { "name": "Rosuvastatin 1", "type": "DRUG" }, { "name": "Rosuvastatin 2", "type": "DRUG" }, { "name": "Rosuvastatin 3", "type": "DRUG" }, { "name": "Rosuvastatin 4", "type": "DRUG" }, { "name": "Placebo to match Rosuvastatin", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 200, "start_date": "2026-09-10", "completion_date": "2027-05-28", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-20T06:08:37.809Z", "location_count": 26, "location_summary": "Sun City West, Arizona • Gardena, California • Lomita, California + 22 more", "locations": [ { "city": "Sun City West", "state": "Arizona" }, { "city": "Gardena", "state": "California" }, { "city": "Lomita", "state": "California" }, { "city": "Pomona", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07619118" }, { "nct_id": "NCT02061761", "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Neoplasms" ], "interventions": [ { "name": "BMS-986016", "type": "BIOLOGICAL" }, { "name": "BMS-936558", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2014-03-13", "completion_date": "2022-02-16", "has_results": true, "last_update_posted_date": "2023-03-24", "last_synced_at": "2026-10-20T06:08:37.809Z", "location_count": 8, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 5 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02061761" }, { "nct_id": "NCT05197075", "title": "A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Immunodeficiency Virus (HIV)" ], "interventions": [ { "name": "DRV/COBI FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 15, "start_date": "2022-08-03", "completion_date": "2022-09-23", "has_results": false, "last_update_posted_date": "2023-09-14", "last_synced_at": "2026-10-20T06:08:37.809Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05197075" }, { "nct_id": "NCT01726517", "title": "Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C Virus" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2012-10", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-10-20T06:08:37.809Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01726517" } ] }